A case of toxic epidermal necrolysis caused by pembrolizumab
10.12173/j.issn.1005-0698.202408019
- VernacularTitle:帕博利珠单抗致中毒性表皮坏死松解症1例
- Author:
Lingling HUANG
1
;
Xialin LI
;
Guangyao HUANG
;
Peng LUO
;
Weimin WANG
;
Junping WANG
Author Information
1. 中国科学院合肥肿瘤医院药学中心(合肥 230000)
- Keywords:
Pembrolizumab;
Lung cancer;
Toxic epidermal necrolysis;
Adverse drug reaction
- From:
Chinese Journal of Pharmacoepidemiology
2024;33(11):1314-1319
- CountryChina
- Language:Chinese
-
Abstract:
A 72-year-old male patient with right lung squamous cell carcinoma treated with 1 cycle of pembrolizumab combination chemotherapy and pembrolizumab 200 mg monotherapy.After 20 days of treatment,a small amount of erythema appeared around the mouth,head,neck,chest and back,accompanied by itching.Then the lesions aggravated progressively,spreading to the head,limbs,buttocks and perianal area,with blisters and epidermal detachment and necrosis,and the lesions involved＞70％of the body surface area,and the pain was obvious.After multidisciplinary consultation,toxic epidermal necrolysis(TEN)was considered.The patient's lesions gradually improved and regressed after treatment with hormones,adjunctive therapy with intravenous immunoglobulin,wound care,infection prevention and nutritional support.TEN adverse reactions were highly likely to be associated with pembrolizumab.This paper reviewed the literature on the cases of TEN induced by pembrolizumab.It analyzed the clinical characteristics and drug treatment strategies of TEN induced by pembrolizumab,to improve clinical staff's ability to recognize and manage immunosuppressant-related skin toxicity and improve the prognosis of tumor patients.
